Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders.
CSF
alzheimer’s disease
biomarker
neurodegeneration
parkinson’s disease
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 May 2022
31 May 2022
Historique:
received:
27
04
2022
revised:
25
05
2022
accepted:
30
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
(1) Background: Alpha-synuclein (α-syn) is a presynaptic neuronal protein that regulates several neuronal functions. In recent decades, the role of α-syn as a biomarker of neurodegenerative diseases has been explored, especially in synucleinopathies. However, only a few studies have assessed its role as biomarker in other neurological disorders. The aim of the study was to evaluate cerebrospinal fluid (CSF) α-syn levels in several neurological disorders; (2) Methods: We measured CSF α-syn levels by a commercial ELISA kit in 158 patients classified in the following group: controls, Alzheimer’s Disease (AD), cerebrovascular diseases, inflammatory central nervous system diseases, other neurological diseases, Parkinson’s Disease (PD), and peripheral neuropathy; (3) Results: Patients with PD showed the lowest and patients with AD the highest levels of CSF α-syn (1372 vs. 2912 pg/mL, respectively, p < 0.001). In AD patients, α-syn levels were significantly associated with tau proteins; (4) Conclusions: α-syn could represent a biomarker of neurodegenerative diseases.
Identifiants
pubmed: 35683523
pii: jcm11113139
doi: 10.3390/jcm11113139
pmc: PMC9181117
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Dement Neuropsychol. 2020 Jul-Sep;14(3):237-242
pubmed: 32973977
Brain Sci. 2021 Jan 17;11(1):
pubmed: 33477387
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Alzheimers Res Ther. 2017 Jul 28;9(1):52
pubmed: 28750675
Sci Transl Med. 2012 Feb 15;4(121):121ra20
pubmed: 22344688
FASEB J. 2003 Oct;17(13):1945-7
pubmed: 14519670
Biomark Med. 2012 Aug;6(4):419-30
pubmed: 22917144
Int J Mol Sci. 2020 Jul 16;21(14):
pubmed: 32708732
Alzheimers Dement (Amst). 2021 May 21;13(1):e12177
pubmed: 34046519
Int Psychogeriatr. 2015 Sep;27(9):1429-38
pubmed: 25851548
Proc Natl Acad Sci U S A. 2020 Mar 3;117(9):4971-4982
pubmed: 32075919
J Neurosci. 2012 Jul 25;32(30):10253-66
pubmed: 22836259
Scand J Clin Lab Invest. 2020 Jul;80(4):313-317
pubmed: 32255379
Mov Disord. 2014 Nov;29(13):1599-605
pubmed: 25258345
J Neurochem. 2019 Apr;149(1):126-138
pubmed: 30125936
Biomark Insights. 2020 Aug 21;15:1177271920950319
pubmed: 32913390
Brain Sci. 2021 Feb 27;11(3):
pubmed: 33673569
Parkinsons Dis. 2015;2015:567386
pubmed: 26336612
J Parkinsons Dis. 2021;11(1):107-121
pubmed: 33325398
PLoS One. 2011;6(7):e22225
pubmed: 21779395
Int J Neurosci. 2015;125(9):645-54
pubmed: 25202803
Lancet Neurol. 2011 Mar;10(3):230-40
pubmed: 21317042
BMB Rep. 2017 May;50(5):237-246
pubmed: 28270301
Lab Med. 2021 Mar 15;52(2):188-196
pubmed: 32926148
Neuropathol Appl Neurobiol. 2016 Feb;42(1):33-50
pubmed: 26662475
Ann Neurol. 2011 Mar;69(3):570-80
pubmed: 21400565
J Neurochem. 2013 May;125(4):512-7
pubmed: 23278133
Mol Neurodegener. 2019 Jun 11;14(1):23
pubmed: 31186026
Transl Neurodegener. 2019 Sep 4;8:28
pubmed: 31508228
Eur J Neurol. 2021 Jun;28(6):1868-1875
pubmed: 33638255
J Neurosci. 2010 May 26;30(21):7281-9
pubmed: 20505094
Brain Sci. 2021 Feb 10;11(2):
pubmed: 33578866
ScientificWorldJournal. 2011;11:1893-907
pubmed: 22125446
J Alzheimers Dis. 2015;43(3):1007-16
pubmed: 25125463
Trends Neurosci. 1998 Jun;21(6):249-54
pubmed: 9641537
Sci Rep. 2017 Jan 10;7:40263
pubmed: 28071698
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Lancet Neurol. 2019 Jun;18(6):573-586
pubmed: 30981640
J Parkinsons Dis. 2015;5(4):699-713
pubmed: 26407041
Mov Disord. 2017 Oct;32(10):1389-1400
pubmed: 28880418
Seizure. 2015 Apr;27:6-9
pubmed: 25891920